Erythropoiesis stimulating agent 
Welcome,         Profile    Billing    Logout  
 69 Companies  52 Products   52 Products   180 Diseases   88 Trials   3683 News 
109 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
recombinant human erythropoietin / Max Planck Institute, Pfizer
2008-000453-35: Open-label phase IIa pilot study exploring safety and potential efficacy of recombinant human erythropoietin in early mild Alzheimer Dementia and therapy-refractory Major Depression (“EPO-AD”)

Ongoing
2
20
Europe
Erypo, Erypo
Max-Planck-Institute of Experimental Medicine
Early, mild dementia of the Alzheimer’s Type and therapy-refractory Major Depression
 
 
Epomax (epoetin omega biosimilar) / Takeda
2004-000678-30: An Evaluation of the Efficacy of Epo-Omega in Treatment of Anaemia in ESRD Patients When Administered by Thrice Weekly Intravenous Injection: A Dose Dependency Evaluation.

Ongoing
2
35
Europe
NEORECORMON, EPOMAX 5000 IU, solution for injection, NeoRecormon Multidose 50,000IU Powder and solvent for solution for injection, NeoRecormon Multidose 50,000IU Powder and solvent for solution for injection
Baxter Healthcare S.A.
Anaemia in End Stage Renal Disease (ESRD) hemodialyzed Patients
 
 
Binocrit (epoetin alfa biosimilar) / Medice, Sandoz
2020-003388-24: Erythropoietin in Trauma

Not yet recruiting
3
2500
Europe
Binocrit 40,000 IU/1 mL solution for injection in a pre-filled syringe, Solution for injection in pre-filled syringe, Binocrit
University College Dublin, Monash University, HRB, NHMRC, Health Research Board
Traumatic injury, Severe injury, Diseases [C] - Injuries, poisonings, and occupational diseases [C21]
 
 
2019-000401-76: Transfusion savings in heart surgery Epargne transfusionnelle en chirurgie cardiaque

Not yet recruiting
3
128
Europe
Solution for injection, Solution for infusion, Solution for infusion in pre-filled syringe, FERINJECT, Venofer, Binocrit
University hospital of Montpellier, University hospital of Montpellier
Heart failure Défaillance cardiaque, Heart failure Défaillance cardiaque, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Surgical Procedures, Operative [E04]
 
 
EPO-TRAUMA, NCT04588311: ErythroPOietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill TRAUMA Patients

Recruiting
3
2500
Europe, RoW
Epoetin Alfa 40000 UNT/ML, Eprex, Binocrit, Sodium Chloride 0.9%, Placebo, Saline
Australian and New Zealand Intensive Care Research Centre, University College Dublin, Medical Research Institute of New Zealand, Medical Research Future Fund, Health Research Board, Ireland, Health Research Council, New Zealand, Irish Critical Care Clinical Trials Network, ANZICS Clinical Trials Group, Monash University
Trauma, Traumatic Injury, Traumatic Brain Injury, Wounds and Injuries, Penetrating Injury, Blunt Injury, Major Trauma, Multiple Trauma
12/25
12/25
ELEMENT-MDS, NCT05949684: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions

Recruiting
3
360
Europe, Canada, Japan, US, RoW
Luspatercept, BMS-986346, ACE-536, Reblozyl®, Epoetin Alfa, Epogen®, PROCRIT®, BINOCRIT
Bristol-Myers Squibb
Myelodysplastic Syndromes
06/27
03/30
darbepoetin alfa (NuPIAO) / 3SBio
NCT06854276: Study of SSS06 for Chemotherapy-Induced Anemia in Non-Myeloid Malignancies

Not yet recruiting
2
80
NA
SSS06, rhEPO, Yibiao
Shenyang Sunshine Pharmaceutical Co., LTD.
Chemotherapy-induced Anemia, Non-myeloid Malignancies
12/27
12/27
recombinant human erythropoietin biosimilar / Hua-Bao Pharma
ChiCTR1900024947: A randomized, open, parallel controlled, single-center clinical trial for recombinant human erythropoietin injection (CHO cells) in the treatment of anemia caused by chemotherapy in non-bone marrow malignant tumors at different times

Recruiting
4
80
 
Recombinant human erythropoietin injection (Jimaixin) 12000 IU/branch, one subcutaneous injection, three times a week (at least one day interval each time) for 8 weeks ;Recombinant human erythropoietin injection (Jimaixin) 12000 IU/branch, 3 branches per time, subcutaneous injection, once a week (3 branches per injection at different parts), for 8 weeks
Anyang Cancer Hospital; North China Pharmaceutical Jintan Biotechnology Co., Ltd., Enterprise self-financing
Tumor anemia
 
 
ChiCTR2000034705: Recombinant human erythropoietin injection (CHO cells) in the treatment of persistent peritoneal dialysis renal anemia: a randomized, positive parallel control, open multicenter clinical trial

Not yet recruiting
4
184
 
12000 IU/ piece, hypodermic injection ;10000 IU/ piece, hypodermic injection
The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine; NCPC Genetech Biotechnology Co.Ltd, Fully self-raised
renal anemia
 
 
EPIAO (recombinant human erythropoietin biosimilar) / 3SBio
EPIAO1: 3SBio Inc. (SSRX) Announces SFDA Approval of High-Dose EPIAO

Completed
3
206
China
EPIAO (recombinant human erythropoietin biosimilar)
3SBio
Anemia
 
 
Hematoboost, NCT05911438: Accelerated Recovery for Total Knee Replacement Surgery With Preoperative Intravenous Iron Combined With Human Erythropoietin for Rapid Hematopoietic Mobilization to Prevent Postoperative Anemia

Not yet recruiting
N/A
419
RoW
Ferric Derisomaltose Injection (Monoferric) and Human Erythropoietin Injection (EPIAO), Basic Treatment
West China Hospital
Total Knee Arthroplasty
12/24
06/25
Epogen (epoetin alfa) / Amgen
NCT05300477: Pharmacological Countermeasures for High Altitude

Active, not recruiting
4
18
US
Acetazolamide, Diamox, Erythropoietin, Procrit
United States Army Research Institute of Environmental Medicine, University of Puget Sound
Hypobaric Hypoxia
09/23
09/25
NCT05078138: Impact of Erythropoietin on Hematological Adaptations and Physical Performance

Completed
4
8
US
Epoetin Alfa
United States Army Research Institute of Environmental Medicine
Exercise-Induced Anemia, Physical Performance
04/23
04/23
NCT04134026: Evaluate the Efficacy and Safety of HIF-PHI for the Treatment of Anemia and Risks of Cardiovascular and Cerebrovascular Events in ESRD Newly Initiated Dialysis Patients

Not yet recruiting
4
400
RoW
HIF-PHI, Epoetin Alfa, Epogen
Second Xiangya Hospital of Central South University
Anemia in Incident Dialysis Patients
10/23
10/24
EpoAid, NCT06670963: Use of Epoetin Alfa and Iron Derisomaltose in Treatment of Anemia in Patients With Sepsis or Septic Shock: a Randomized Controlled Trial

Recruiting
4
200
Europe
Iron, EPO, 0.9 % NaCl
Piotr Czempik
Anemia, Sepsis, Septic Shock
12/26
04/27
NCI-2009-01173, NCT00843882: Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

Active, not recruiting
3
247
US
Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Epoetin Alfa, EPO, Epoetin alfa-epbx, Epogen, Eprex, Procrit, Retacrit, Laboratory Biomarker Analysis, Lenalidomide, CC 5013, CC-5013, CC5013, CDC 501, Revlimid
National Cancer Institute (NCI)
Anemia, Chronic Myelomonocytic Leukemia, De Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome
07/19
10/25
EPO-PRETAR, NCT03223961: A Trial Testing Early Vs Late Onset of EPO Alfa Treatment in Lower Risk MDS

Active, not recruiting
3
124
Europe
EPREX, Epoetin alfa
Groupe Francophone des Myelodysplasies
Myelodysplastic Syndromes
09/23
10/28
PAEAN, NCT03079167 / ACTRN12614000669695: - Erythropoietin for Hypoxic Ischaemic Encephalopathy in Newborns

Completed
3
313
RoW
Epoetin Alfa, Epogen, Procrit, Normal saline, 0.9% NaCl
University of Sydney, National Health and Medical Research Council, Australia
Hypoxic-Ischemic Encephalopathy
11/23
04/24
COMMANDS, NCT03682536 / 2017-003190-34: A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve

Hourglass Jan 2022 - Dec 2022 : Submission for anaemia
Checkmark Data from COMMANDS trial for patients with 1L lower-risk MDS
Oct 2022 - Oct 2022: Data from COMMANDS trial for patients with 1L lower-risk MDS
Hourglass May 2020 - Dec 2020 : Market entry for MDS
Hourglass Aug 2020 - Dec 2020 : Market entry in EU for myelodysplastic syndrome and beta-thalassemia
Active, not recruiting
3
363
Europe, Canada, Japan, US, RoW
Luspatercept, ACE-536, Epoetin alfa, EPREX®, ERYPO®, PROCRIT®
Celgene, Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Myelodysplastic Syndromes
03/23
09/27
VOICE, NCT06520826: Vafseo Outcomes In-Center Experience

Recruiting
3
2200
US
Vadadustat, Vafseo, Erythropoiesis Stimulating Agent, Epoetin alfa (EPOGEN), Methoxy polyethylene glycol-epoetin beta (Mircera), or Darbepoetin alfa (Aranesp)
USRC Kidney Research, Akebia Therapeutics
Anemia of Chronic Kidney Disease
06/26
06/26
ENCASE, NCT06352138: Comparative Study of Two Recombinant Human Erythropoietin Products in Chronic Kidney Disease Patients

Not yet recruiting
3
280
RoW
Experimental: Epoetin alfa Megalabs® Erythropoietin injectable in intravenous administration., Epoetin alfa Megalabs®, Human recombinant epoetin alfa, Active comparator: European Union licenced epoetin alfa, Epogen®, Human recombinant epoetin alfa
Megalabs, Azidus Laboratories
Anemia of Chronic Kidney Disease
03/27
03/27
ACTRN12613000504718: Dose finding study for Polysialylated Erythropoietin (PSA-EPO) in Chronic Kidney Disease (CKD) subjects

Recruiting
2
90
 
Xenetic Biosciences PLC, Xenetic Biosciences PLC
Anaemia in Chronic Kidney Disease
 
 
NCT05265325: A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis

Completed
2
175
US, RoW
AND017 capsules TIW, AND017 capsules QW, epoetin alfa, darbepoetin alfa, Mircera®, or their biosimilars
Kind Pharmaceuticals LLC
Renal Anemia
02/24
04/24
ACHiEvE-SCD, NCT05451940: Hydroxyurea and EPO in Sickle Cell Disease

Completed
1/2
17
US, RoW
Hydroxyurea, Droxia, Hydrea, and hydroxycarbamide., Epoetin Alfa, EPO, epoetin, erythropoietin, erythropoiesis-stimulating agent, ESA, haematopoietin, haemopoietin
Julia Xu, Carnegie Mellon University, American Society of Hematology
Anemia, Sickle Cell, Sickle Cell Disease
12/24
02/25
EVEREST, NCT06832189: EVR and EPO for Liver Transplant Tolerance

Not yet recruiting
1
20
US
Everolimus, Zortress, Epoetin alfa, EPO, Erythropoietin, Procrit
National Institute of Allergy and Infectious Diseases (NIAID)
Liver Transplant
06/30
06/30
NCT00090935: Epoetin Alfa in Treating Cancer-Related Anemia in Patients With Non-Myeloid Cancer Who Are Not Currently Receiving Chemotherapy or Radiation Therapy

Active, not recruiting
N/A
US
epoetin alfa
Jonsson Comprehensive Cancer Center, National Cancer Institute (NCI)
Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
 
 
NCT03061565: Long Term Effects of Erythropoietin in Patients With Moderate to Severe Traumatic Brain Injury

Completed
N/A
356
RoW
erythropoietin, EPOETIN ALFA, Placebos, Sodium chloride
Australian and New Zealand Intensive Care Research Centre, Monash University
Traumatic Brain Injury
07/22
12/22
CA056-1083, NCT06581055: A Retrospective Study to Describe Real-World Treatment Patterns and Clinical Outcomes Among Patients With Myelodysplastic Syndromes

Withdrawn
N/A
86
RoW
Luspatercept, Epoetin Alfa
Bristol-Myers Squibb
Myelodysplastic Syndromes (MDS)
03/25
03/25
Mircera (methoxy polyethylene glycol-epoetin beta) / Roche, CSL Behring
2009-011497-15: PILOT CLINICAL TRIAL WITH MIRCERA (methoxy polyethylene glycol-epoetin beta) IN DIALYSIS UNIT OF A.O. SAN GIOVANNI BATTISTA DI TORINO

Ongoing
4
21
Europe
MIRCERA*IV SC FL 200MCG 1ML, MIRCERA*IV SC FL 200MCG 1ML
AZIENDA SANITARIA OSPEDALIERA \"S. GIOVANNI BATTISTA DI TORINO\"
End stage renal patients in hemodialysis or peritoneal dialysis treatment
 
 
ROQ-IT, NCT05951192: A Prospective Interventional Study Assessing the Clinical and Operational Effectiveness of Transitioning From Mircera to Daprodustat for the Treatment of Anemia in End Stage Kidney Disease

Completed
4
161
US
Daprodustat, JESDUVROQ
USRC Kidney Research, GlaxoSmithKline
Anemia, Renal Insufficiency, Chronic, Renal Anemia
02/24
02/24
2010-021355-85: Etude nationale, multicentrique, prospective, évaluant la correction et le maintien du taux d’hémoglobine avec une administration sous-cutanée mensuelle de Mircera® chez des patients transplantés rénaux depuis plus de 6 mois présentant une anémie symptomatique traitée ou non par ASE

Ongoing
3
158
Europe
RO 503821/F03, MIRCERA, MIRCERA
CHU AMIENS
Anémie symptomatique chez le patient transplanté rénal
 
 
NCT04707768: Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects

Completed
3
456
US
Vadadustat, Mircera®
Akebia Therapeutics
Anemia Associated With Chronic Kidney Disease (CKD)
01/23
01/23
NCT04155125: A Study of Efepoetin Alfa in Treating Anaemia Associated With Chronic Kidney Diseases Patient

Completed
3
391
RoW
efepoetin alfa, Mircera
PT Kalbe Genexine Biologics, Novotech (Australia) Pty Limited
Anaemia Associated With Chronic Kidney Disease
03/22
06/23
NCT01892202: A Non-Interventional Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Patients With Chronic Kidney Disease Not on Dialysis

No Longer Available
N/A
RoW
Cohort
Hoffmann-La Roche
Anemia
02/11
02/11
ReliPoietin (recombinant human erythropoietin biosimilar) / Reliance Life Sci
Relipoietin1: A clinical trial to evaluate efficacy and safety of Relipoietin in patients with anemia due to Kidney disease

Completed
3
75
India
ReliPoietin (recombinant human erythropoietin biosimilar)
Reliance Life Sciences
Anemia
 
 
Nanokine (epoetin alfa biosimilar) / Nanogen Biopharma
EPO, NCT06919861: Pharmacokinetics, Pharmacodynamics, and Safety of Nanokine Produced by Nanogen Pharmaceutical Joint Stock Company

Not yet recruiting
1
44
NA
Erythropoietin alfa, Nanokine, Eprex
Nanogen Pharmaceutical Biotechnology Joint Stock Company
Natural Blood and Blood Product Toxicity
10/25
12/25
Repotin (recombinant human erythropoietin biosimilar) / Genius Biotherapeutics
epoetinZydCad: A clinical trial to study the effects of epoetin in patients with chronic renal failure

Completed
3
80
India
epoetin alfa biosimilar - Zydus Cadila
Zydus Cadila
Chronic Renal Failure
 
 
Epoyet (epoetin alfa biosimilar) / Procaps, Biogalenic, Delta Farma, Biosidus, Pentafarma
NCT04036253: Study of HEMAX PFS Versus EPREX/ ERYPO® in Predialysis Chronic Kidney Disease

Completed
3
43
RoW
Erythropoietin alfa
Bio Sidus SA
Anemia of Chronic Kidney Disease
06/21
08/21
Eprex (epoetin alfa) / J&J
2012-002076-14: Pre-operative treatment with Erythropoietin and iron supplement for prevention of perioperative blood transfusion in cardiac surgery Pre-operatieve behandeling met Erythropoietin en ijzer supplement ter voorkoming van peri-operatieve bloedtransfusie bij hartchirurgie.

Ongoing
4
100
Europe
EPREX, Ferinject, RVG33268, B03A C01, Suspension for injection in pre-filled syringe, Solution for injection/infusion, EPREX, Ferinject
Patients (male and female) scheduled for coronary artery bypass grafting surgery (CABG) or single Aortic Valve replacement (AVR) on conventional cardiopulmonary bypass., bloodloss in cardiac surgery, Diseases [C] - Cardiovascular Diseases [C14]
 
 
2011-000123-33: The use of erythropoietin (rhEPOa) in patients with stroke to see if it can aid and speed up the recovery and regrowth of new nerve cells.

Ongoing
4
90
Europe
EPREX, EPREX 40,000 IU/ml, solution for injection in pre-filled syringe., EPREX 40,000 IU/ml, solution for injection in pre-filled syringe.
King\'s College Hospital NHS Foundation Trust, King\'s College London, National Institute of Health Research
Stroke
 
 
2007-005831-27: Use of rHuEpo before autologous hematopoietic stem cell transplantation in patients affected by multiple myeloma, non Hodgkin disease and breast cancer to reduce transfusional requirement after myeloablative conditioning. A monocentric, phase III, open study.

Ongoing
3
90
Europe
EPREX, EPREX
AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA\' GRANDA (A.O. DI RILIEVO NAZIONALE)
autologous hematopoietic stem cells transplantation in patients affected by multiple myeloma, non Hodgkin disease and breast cancer
 
 
2009-016066-91: SAFETY AND EFFICACY OF ERYTHROPOIETIN IN AMYOTROPHIC LATERAL SCLEROSIS: A RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL

Ongoing
3
160
Europe
EPREX*1SIR 40000UI/ML 1ML, EPREX*1SIR 40000UI/ML 1ML
ISTITUTO NEUROLOGICO \"CARLO BESTA\"
ALS
 
 
2017-000812-41: A RANDOMIZED TRIAL TESTING EARLY VERSUS LATE ONSET OF EPO ALFA TREATMENT IN LOWER RISK MDS WITH NON RBC TRANSFUSION DEPENDENT ANEMIA AND WITHOUT DEL 5Q Etude randomisée évaluant l’introduction précoce versus tardive de l’Epoétine Alfa (EPREX®) chez les patients atteints de syndromes myélodysplasiques de bas risque

Not yet recruiting
3
124
Europe
Eprex, Injection, EPREX
GFM-Groupe Francophone des Myélodysplasies, Janssen
Adult subject (18 years of age older) with low or intermediate-1 IPSS risk MDS with transfusions independent anemia patients adultes (18 ans ou plus) avec SMD de risque IPPS faible ou intérmédiaire-1 présentant une anémie non-dépendante des transfusions, Adult subject (18 years of age older) with low or intermediate-1 IPSS risk MDS with transfusions independent anemia patients adultes (18 ans ou plus) avec SMD de risque IPPS faible ou intérmédiaire-1 présentant une anémie non-dépendante des transfusions, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2011-001329-26: Erythropoietin in Amyotrophic Lateral Sclerosis: a study to identify the best dose and the optimal route of administration and evaluate the safety Eritropoietina nella Sclerosi Laterale Amiotrofica: uno studio per identificare la dose e la via di somministrazione ottiminali e valutarne la sicurezza

Ongoing
2
40
Europe
Solution for injection, EPREX*1SIR 40000UI/ML 1ML
ISTITUTO NEUROLOGICO "CARLO BESTA", ARISLA
Amyotrophic Lateral Sclerosis Sclerosi Laterale Amiotrofica, Degenerative motoneuron disease Malattia degenerativa dei motoneuroni, Diseases [C] - Nervous System Diseases [C10]
 
 
2007-000994-40: ESTUDIO MULTICENTRICO PROSPECTIVO, DOBLE CIEGO, CONTROLADO CON PLACEBO, ALEATORIZADO, DE TRES GRUPOS PARALELOS PARA EVALUAR LA EFICACIA Y SEGURIDAD DEL TRATAMIENTO CON ERITROPOYETINA RECOMBINANTE HUMANA EN LA PREVENCIÓN DE LA NEFROTOXICIDAD ASOCIADA A LA UTILIZACIÓN DE CONTRASTES YODADOS EN PACIENTES CON ALTO RIESGO DE DISFUNCIÓN RENAL.

Ongoing
2
198
Europe
NEORECORMON 50.000 UI, EPREX 40.000 UI/1 ml, EPOPEN 40.000 UI/1 ml solución inyectable en viales, NEORECORMON 50.000 UI, EPREX 40.000 UI/1 ml, EPOPEN 40.000 UI/1 ml solución inyectable en viales
Hospital General \"Gregorio Marañón\"
Pacientes diagnosticados de enfermedad vascular periférica o coronaria, sometidos a procedimientos radiológicos diagnósticos o intervencionistas que incluyan la utilización de radiocontrastes, con alto riesgo de desarrollar nefropatía de contraste (Score de Mehran de >9 previo al procedimiento)
 
 
2015-002255-10: Can artificially made human erythropoietin improve recovery after major injuries?

Ongoing
2
10
Europe
Eprex (rhEPO), NA, Solution for injection in pre-filled syringe, Eprex
Abertawe Bro Morgannwg University Health Board, Abertawe Bro Morgannwg University Health Board
Post-trauma multiple organ failure: a manifestation of the systemic inflammatory/immune response to major injuries., This study will see if artificially made human erythropoietin helps people recover from serious injury quicker by boosting immunity through bone marrow or improving the way the body creates energy., Body processes [G] - Immune system processes [G12]
 
 
PRETEC-EPO, NCT03315897 / 2016-004023-24: Effects of Erythropoietin on Cognition and Neural Activity in Mood Disorders

Completed
2
103
Europe
Erythropoietin, Eprex, EPO, Saline, Placebo
Lars Vedel Kessing, Mental Health Services in the Capital Region, Denmark, Lundbeck Foundation
Bipolar Disorder, Cognitive Impairment, Unipolar Depression
10/22
10/22
EPO-T, NCT03339596 / 2016-002326-36: Effects of Erythropoietin for Cognitive Side-effects of ECT

Completed
2
60
Europe
Erythropoietin, Eprex, EPO, Saline, Placebo
Martin Balslev Jørgensen, The Augustinus Foundation, Denmark., Mental Health Services in the Capital Region, Denmark
ECT, Cognitive Impairment, Unipolar Depression, Bipolar Depression
01/23
02/23
2021-000596-37: A randomized phase I/ II multicenter study evaluating combination of luspatercept in LR-MDS without RS having failed or being ineligible to ESA Étude multicentrique de phase I/II randomisée évaluant luspatercept seul ou en association avec l’ASE (Agent Stimulant l’Erythropoïèse) dans les Syndromes Myélodysplasiques de faible risque non sidéroblastiques en échec ou non éligibles aux Agents Stimulants l’érythropoïèse

Ongoing
1/2
150
Europe
Eprex, Lyophilisate for solution for injection, Solution for injection, Reblozyl, EPREX
Groupe Francophone des Myélodysplasies, Celgene/BMS
Low risk myelodysplastic syndrom without RS having failed or being ineligible to Erythroid Stimulating Agent Syndromes Myélodysplasiques de faible risque non sidéroblastiques en échec ou non éligibles aux agents stimulants l’érythropoïèse, Low risk myélodysplastic syndrom without RS having failed or being ineligible to Erythroid Stimulating Agent Syndromes Myelodysplasiques de faible risque non sidéroblastiques en échec ou non éligibles aux agents stimulants l’érythropoïèse, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT05181735: Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA

Recruiting
1/2
150
Europe
Luspatercept Injection [Reblozyl], ACE-536, Eprex, Epoietin alfa
Groupe Francophone des Myelodysplasies, Celgene
MDS, Myelodysplastic Syndromes
12/28
06/29
2006-006898-24: Etude TETRAM 2 : Traitement par l’Epo des TRAumatisés Médullaires : recherche de la dose maximum tolérée

Ongoing
1
20
Europe
EPREX®, EPREX, EPREX
HOSPICES CIVILS DE LYON
traumatisme médullaire déficitaire (TMD)
 
 
RUBI, NCT04954989: Biosimilarity Study of Intravenous Recombinant Human Erythropoietin in Healthy Volunteers

Not yet recruiting
1
52
RoW
Experimental Erythropoietin subcutaneous injection single dose of 4,000 IU, Active comparator Erythropoietin subcutaneous injection single dose of 4,000 IU
Megalabs
Healthy
12/24
12/24
ErepoXen (polysialylated erythropoietin) / Xenetic Biosci, Serum Institute of India, Pharmsynthez
ErepoXen1: Dose finding study for Polysialylated Erythropoietin (PSA-EPO) in Chronic Kidney Disease (CKD) subjects

Recruiting
2
90
Australia, New Zealand
ErepoXen (polysialylated erythropoietin)
Xenetic Biosciences
Chronic Kidney Disease
 
 
Eporatio (epoetin theta biosimilar) / Merckle Biotec, Teva
ChiCTR1900024213: Clinical Trial of BioPoint ALT-1 Test

Not yet recruiting
N/A
 
Jiangsu Province Hospital; JiangSu Province Hospital, Projects to “improve capacity building for prevention and control of infectious diseases”
Liver diseases
 
 
HyPoietin (epoetin alfa biosimilar) / GC Biopharma, Genexine, Fosun Pharma
NCT06466785: A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis

Recruiting
3
429
RoW
Efepoetin Alfa, GX-E4, Darbepoetin Alfa, Aranesp®
Genexine, Inc., PT Kalbe Genexine Biologics
Anemia of Chronic Kidney Disease
12/26
09/27
GX-E4-HV-003, NCT06490939: Clinical Trial of Efepoetin Alfa in Healthy Subjects

Recruiting
1
40
RoW
Efepoetin Alfa, GX-E4
Genexine, Inc.
Healthy
02/25
10/25
Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin
2005-003057-28: An Investigation Into the Prevalence, Cause and treatment of Unexplained Anamia in Diabetes

Ongoing
4
1000
Europe
Neorecormon, Aranesp, N/A, Neorecormon, Aranesp, Neorecormon, Aranesp
University Hospital Aintree NHS Trust
Anaemia in Diabetes
 
 
2010-020401-32: IDENTIFICATION OF OXIDATIVE-STRESS AND MICROINFLAMMATION GENES MODULATED BY ERYTHROPOIETIN ADMINISTRATION IN PATIENTS WITH RENAL TRANSPLANT AND CHRONIC RENAL FAILURE. PERSPECTIVES FOR ERYTHROPOITIN PHARMACOGENOMICS.

Ongoing
4
20
Europe
ARANESP, ARANESP
AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE
PATIENTS WITH RENAL TRANSPLANT AND CHRONIC RENAL FAILURE
 
 
NCT05864261: Pharmacokinetics Comparison Study of JT1801 and NESP® After Single Dose Administration in Chinese Health Male Volunteers

Completed
4
74
RoW
JT1801 60ug, NESP 60ug
Yi Fang
Renal Anemia
08/23
08/23
ChiCTR2200057105: The effect of darbepoetin alfa on patients with chronic renal disease and renal anemia (A real-world study)

Not yet recruiting
4
 
Shenzhen Second People's Hospital, the First Affiliated Hospital of Shenzhen University; Shenzhen Second People's Hospital, the First Affiliated Hospital of Shenzhen University, None
chronic kidney disease and renal anemia
 
 
ChiCTR2500096455: Protocol for Comparing Hemoglobin Control between Darbepoetin Alfa and Short-acting rHuEPO in Maintenance Hemodialysis Patients

Not yet recruiting
4
410
 
No; No
Shenzhen Second People's hospital; Shenzhen Second People's hospital, National Natural Science Foundation of China (81900639); Basic Research Program of Shenzhen Science and Technology R&D Fund (JCYJ20190806162807125); Shenzhen Key Medical Discipline Construction Fund (SZXK009); Sanming Project of Medicine in Shenzhen(SZSM201512004)
Renal anemia
 
 
2007-001904-18: An open label randomised controlled study to compare the efficacy, safety and tolerability of once every four weeks administration of subcutaneous C.E.R.A. versus darboepoetin alfa for the maintenance of haemoglobin levels in predialysis patients with chronic renal anaemia.Estudio abierto, randomizado, controlado para comparar la eficacia, seguridad y tolerancia de la administración una vez cada cuatro semanas de C.E.R.A. por vía subcutánea frente a darbepoetina alfa para el mantenimiento de las concentraciones de hemoglobina en pacientes con anemia renal crónica que no están en diálisis.

Ongoing
3
297
Europe
C.E.R.A., C.E.R.A, RO0503821, Aranesp®, Aranesp®
ROCHE FARMA S.A.
Anemia en insuficiencia renal crónica
 
 
2007-001905-10: \"Estudio abierto, randomizado, controlado para comparar la eficacia, seguridad y tolerancia de la administración una vez cada cuatro semanas de C.E.R.A por vía subcutánea frente a darbepoetina alfa para el mantenimiento de las concentraciones de hemoglobina en pacientes receptores de trasplante renal con anemia renal crónica \"\"An open label randomised controlled study to compare the efficacy, safety and tolerability of once each four weeks administration of subcutaneous C.E.R.A. versus darbepoetin alfa for the maintenance of haemoglobin levels in renal transplant recipients with chronic renal anaemia\"

Ongoing
3
297
Europe
C.E.R.A, RO0503821, Aranesp, Aranesp
Roche Farma S.A
Nefropatía crónica en pacientes transplantados
 
 
2007-003509-28: Intérêt de l’administration intra-coronaire d’une dose unique d’EPO lors de la reperfusion chez des patients hospitalisés pour un primo infarctus avec sus-décalage persistant du segment ST

Ongoing
3
54
Europe
ARANESP, ARANESP, ARANESP
CHRU Montpellier - Direction de la Recherche, Partenariats et Réseaux, Relations avec l\'Université
Patients hospitalisés pour un primo infarctus avec sus-décalage persistant du segment ST
 
 
2017-000583-15: Randomized controlled trial on the use of darbepoetin alfa to reduce red cell transfusions in newborns with hemolytic disease due to red cell alloimmunization treated with intrauterine transfusions

Ongoing
3
40
Europe
Solution for injection, Aranesp
Leiden University Medical Center, Sanquin Blood Supply
Hemolytic disease of the newborn due to red blood cell alloimmunization, Anemia in the newborn due to red cell antibodies received from the mother (for example rhesus D hemolytic disease), Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
 
 
NCT05585645: A Study to Compare Efficacy and Safety of Nanogen's Darbepoetin Alfa With Aranesp® (Amgen) in the Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis (CKD)

Completed
3
214
RoW
Stimus (NNG-DEPO)
Nanogen Pharmaceutical Biotechnology Joint Stock Company, Vietstar Biomedical Research, MEDPHASE CLINICAL RESEARCH CONSULTANT COMPANY LIMITED, CLINICAL RESEARCH VIET NAM SKILL TRAINING AND CONSULTING COMPANY LIMITED, MedProve Inc
Anemia, Chronic Kidney Disease Requiring Chronic Dialysis
11/22
11/22
NCT05768997: High Dose IV Iron Plus ESA in Chemotherapy-induced Anemia

Recruiting
3
312
RoW
Ferric Derisomaltose Injection, Darbepoetin Alfa Injection
Hallym University Medical Center
Anemia
12/25
12/25
ACTRN12605000731695: Phase II study of the addition of darbepoetin alfa (Aranesp) and pegfilgrastim (Neulasta) support for optimal dose-dense chemotherapy for early breast cancer

Not yet recruiting
2
30
 
Mater Adult hospital, Mater Adult Hospital
Breast Cancer
 
 
ACTRN12606000030572: An open label phase 2 study of doxorubicin and cyclophosphamide followed by paclitaxel (AC-T) delivered every 14 days with pegfilgrastim and darbepoetin alfa support for the adjuvant treatment of women with breast cancer

Recruiting
2
80
 
Amgen Australia, Amgen Australia
Early stage breast cancer
 
 
NCT00039247: Darbepoetin Alfa in Treating Anemia in Patients With Cancer Who Are Receiving Chemotherapy

Active, not recruiting
2
NA
darbepoetin alfa
Jonsson Comprehensive Cancer Center, National Cancer Institute (NCI)
Anemia, Unspecified Adult Solid Tumor, Protocol Specific
 
 
2007-003153-90: Traitement par érythropoïétine de l\'anémie associée à la bronchopneumopathie chronique obstructive : conséquences fonctionnelles à l\'effort

Ongoing
2
20
Europe
ARANESP, ARANESP, ARANESP
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
Anémie associée à la BPCO
 
 
2007-007137-38: En åbent randomiseret fase II undersøgelse af effekten af darbepoietin alfa (Aranesp®) til behandling af anæmi hos patienter med hormonrefraktær prostatacancer, der behandles med Taxotere

Ongoing
2
100
Europe
Aranesp, Aranesp, Aranesp
Vejle Hospital
Patients with advanced prostate cancer and anaemia
 
 
2007-007653-31: Estudio aleatorizado, doble ciego, controlado con placebo, de 6 meses de duración para evaluar la eficacia de eritropoyetina recombinante humana en pacientes con ataxia de Friedreich.Randomized, double-blind, placebo-controlled 6 months study to evaluate the efficacy of rhuEPO in patients with Friedreich?s ataxia.

Ongoing
2
30
Europe
ARANESP 10 microgramos solución inyectable en jeringa precargada, ARANESP 20 microgramos solución inyectable en jeringa precargada, ARANESP 30 microgramos solución inyectable en jeringa precargada, ARANESP 50 microgramos solución inyectable en jeringa precargada, ARANESP 60 microgramos solución inyectable en jeringa precargada, ARANESP 80 microgramos solución inyectable en jeringa precargada, ARANESP 100 microgramos solución inyectable en jeringa precargada, ARANESP 130 microgramos solución inyectable en jeringa precargada, ARANESP 150 microgramos solución inyectable en jeringa precargada, ARANESP 10 microgramos solución inyectable en jeringa precargada, ARANESP 20 microgramos solución inyectable en jeringa precargada, ARANESP 30 microgramos solución inyectable en jeringa precargada, ARANESP 50 microgramos solución inyectable en jeringa precargada, ARANESP 60 microgramos solución inyectable en jeringa precargada, ARANESP 80 microgramos solución inyectable en jeringa precargada, ARANESP 100 microgramos solución inyectable en jeringa precargada, ARANESP 130 microgramos solución inyectable en jeringa precargada, ARANESP 150 microgramos solución inyectable en jeringa precargada
Fundación Investigación Biomédica Hospital La Paz
Ataxia de FriedreichFriedreich´s ataxiaCIE : 334,0
 
 
2017-002268-42: Anemia Studies in CKD: Erythropoiesis via a Novel PHI Daprodustat –Forearm Blood Flow (ASCEND-FBF)

Not yet recruiting
2
62
Europe
daprodustat 1mg, daprodustat 2mg, daprodustat 4mg, Darbepoetin alfa, Tablet, Solution for injection in pre-filled syringe, Aranesp
GlaxoSmithKline Research & Development Ltd, GlaxoSmithKline R&D
anemia associated with chronic kidney disease, anemia associated with chronic kidney disease, Body processes [G] - Physiological processes [G07]
 
 
EDEN, NCT04432662: Darbepoetin in Neonatal Encephalopathy Trial

Recruiting
2
150
Europe
Darbepoetin Alfa
Imperial College London
Neonatal Encephalopathy
09/24
09/24
DINOSAUR, NCT03171818: Darbepoetin for Ischemic Neonatal Stroke to Augment Regeneration

Recruiting
2
80
Europe
Darbepoetin Alfa, Aranesp, Saline, Sodium Chloride
UMC Utrecht, Alberta Children's Hospital, The Hospital for Sick Children
PAIS, Neonatal Stroke, Perinatal Stroke
12/24
06/25
FOXTROT, NCT05810311: The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy

Not yet recruiting
2
30
Europe
Roxadustat, Evrenzo, Darbepoietin Alfa, Aranesp
Region Stockholm
Diabetes Complications, Diabetes; Nephropathy (Manifestation)
01/27
12/27
DIVI, NCT05340465: Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants

Recruiting
2
120
US
Darbepoetin Alfa, Aranesp, Darbe, Low Molecular Weight Iron Dextran, INFeD, LMW-ID, Ferumoxytol injection, Feraheme, FMX, Oral iron supplements, Ferr-in-sol
University of Washington, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Prematurity, Iron-deficiency, Iron Deficiency Anemia, Iron Malabsorption
12/25
12/27
NCT04798339: Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA

Active, not recruiting
1/2
13
US
Canakinumab Injection, Ilaris, Darbepoetin Alfa, Aranesp
H. Lee Moffitt Cancer Center and Research Institute, Novartis Pharmaceuticals
Myelodysplastic Syndromes
05/25
10/25
CKD, NCT05636891: Pharmacokinetic/Pharmacodynamic Parameters of NNG-DEPO (Stimus) With Aranesp® (Amgen) in Treatment of Anemia in Patients on Dialysis

Completed
1
43
RoW
Stimus
Nanogen Pharmaceutical Biotechnology Joint Stock Company, Vietstar Biomedical Research, Clinical Research Consultants, Inc., Clinical Research Viet Nam Skill Training And Consultant Company Limited
Chronic Kidney Disease
11/22
11/22
SMART, NCT05936021: Clinical Validation Study for Optimization of Anemia MAnagement in Hemodialysis Patients With End Stage Kidney Disease Using the Dialysis Anemia TReatmenT Model

Active, not recruiting
N/A
80
US
Algorithm model-based Aranesp doses, Standard of care
Intermountain Health Care, Inc.
Dialysis
11/24
01/25
EPOASA, NCT04330729: The Effect of Salicylate on Platelet Function in CKD (Chronic Kidney Disease) Patients Treated With Aranesp

Recruiting
N/A
60
Europe
Acetylsalicylic acid
Zealand University Hospital
Erythropoietin Adverse Reaction
12/26
12/26
fezagepras (PBI-4050) / Liminal BioSci
2016-004823-21: A Rollover Study of PBI-4050 (study drug) in Patients with Alström Syndrome

Not yet recruiting
2
30
Europe
PBI-4050, Capsule, soft
Prometic Biosciences Inc., Prometic Biosciences Inc.
Alström Syndrome, A rare genetic disorder caused by mutations in the gene ALMS1, Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
 
 
EPEG (pegylated recombinant erythropoietin) / Cadila, Prolong Pharma
ACTRN12613000374763: A Phase 1 Single Blind, Randomized, Single-Dose, Safety, Tolerability, Pharmacodynamic, and Pharmacokinetic Study of ZY7318 (pegylated recombinant human erythropoietin) in Healthy Volunteers

Recruiting
1
32
 
Prolong Pharmaceuticals, LLC, Prolong Pharmaceuticals, LLC
Healthy volunteers study and investigational product would be targeted for secondary anemia due to renal cause.
 
 
Erysaa (epoetin alfa biosimilar) / PanGen Biotech, CCM Pharma
PDA10a: CCM Duopharma Biotech Berhad To Commence Historic Phase III Clinical Trials For Treatment Of Kidney Failure

Ongoing
3
300
Malaysia
PDA10 (epoetin alfa biosimilar)
PanGen Biotech
Kidney Failure
 
 
APO-EPO (epoetin alfa biosimilar) / Apotex
2011-005057-31: Study of safety and efficacy of APO-EPO versus US licensed Procrit® in patients with anemia of chronic kidney disease stage 5D

 
3
155
Europe
n/a, APO-EPO, n/a, Procrit®, Procrit®
APOTEX Inc., APOTEX Inc.
Anemia and chronic kidney disease stage 5D (patients on stable hemodialysis)
 
 
pegol sihematide (EPO-018B) / Jiangsu Hansoh Pharma
NCT06946394: Two Different Regiments of Pegmolesatide for Anemia in Patients With Chronic Kidney Disease Not Receiving Dialysis

Not yet recruiting
4
160
NA
Pegmolesatide, EPO-018B
The First Affiliated Hospital of Dalian Medical University, Jiangsu Hansoh Pharmaceutical Co., Ltd.
Renal Anemia in Non-dialysis Chronic Kidney Disease
06/26
11/26
NCT03902691: Study of the Efficacy and Safety of Pegol-Sihematide for Anemia in Patients With Chronic Kidney Disease on Dialysis

Completed
3
372
RoW
Pegol-Sihematide, ESPO
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Chronic Kidney Diseases
02/21
05/22
NCT03903809: Study of the Efficacy and Safety of Pegol-Sihematide for Anemia in Patients With NDD-CKD

Active, not recruiting
3
175
RoW
Pegol-Sihematide, HS-20039, ESPO, Recombinant Human Erythropoietin Injection
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Non-Dialysis-Dependent Chronic Kidney Disease
10/21
12/22
Epoch (epoetin beta biosimilar) / Roche
2006-004775-35: The Effect of Treating Patients with Anaemia in Diabetic Nephropathy to different target haemoglobin levels with Epoetin Beta

Ongoing
4
120
Europe
NeoRecormon, NeoRecormon
Barts and the London NHS Trust
Anaemia in Diabetic Nephropathy
 
 
2006-003502-26: A randomised control trial of the use of Epoetin Beta in the treatment of Post Transplant Anaemia

Ongoing
4
120
Europe
NeoRecormon, NeoRecormon
Barts and the London NHS Trust
Post Transplant Anaemia
 
 
2006-005373-22: Erythropoietin and Delayed Graft Function in Renal Allografts from Extended Criteria Donors.

Ongoing
4
40
Europe
NeoRecormon, NeoRecormon
Central Manchester and Manchester Children\'s University Hospitals NHS Trust
Transplantation of renal allografts from extended criteria donors
 
 
2007-001751-19: Estudio aleatorizado, unicéntrico, fase IV, para evaluar la corrección de la anemia asociada a la estenosis aórtica severa.

Ongoing
4
90
Europe
Neorecormon 10.000 U/semanales, Tardyferon, Neorecormon 10.000 U/semanales, Tardyferon
Dr. Miquel Gómez. Servicio de Cardiología. Hospital del Mar
Anemia asociada a la estenosis aórtica severa.
 
 
2007-001325-96: Estudio de dos pautas de hierro intravenoso para la optimización del tratamiento con epoetina recombinante humana en pacientes con anemia inducida por la radio quimioterapia

Ongoing
4
78
Europe
Venofer, Neorecormon, Venofer, Neorecormon, Venofer, Neorecormon
Pilar Samper Ots
Anemia en pacientes adultos con tumores sólidos tratados con radio-quimioterapia.
 
 
2008-003733-24: A randomised study to assess the effects of Epoetin Beta on renal function in patients with critical illness(with or without multi-organ failure)

Ongoing
4
30
Europe
Neo-recormon, EU/1/97/031/030, Neorecormon solution for injection (pre filled syringe), Neorecormon solution for injection (pre filled syringe)
Abertawe Bro Morgannwg University NHS Trust, Abertawe Bro Morgannwyg University Health Board
Sepsis/Acute renal failure
 
 
2006-003727-37: A randomized, open label, multicentre trial to define the most effective haemoglobin concentration to start erythropoietin beta (neoRecormon) therapy in anaemic subjects with lymphoproliferative malignancy receivin chemotherapy\"REPOS\"study

Ongoing
3
150
Europe
NeoRecormon,
Haga Teaching Hospital
Anemia in cancer patients
 
 
2009-011187-11: “Estudio fase III multicéntrico, aleatorizado y abierto de dos pautas de hierro intravenoso en combinación con epoetina beta para el tratamiento de la anemia inducida por quimioterapia en pacientes con cáncer no mieloide avanzado”.

Ongoing
3
200
Europe
VENOFER 20 mg/ml solución inyectable o concentrado para solución para perfusión, NEORECORMON 30000 UI/solución inyectable en jeringa precargada, VENOFER 20 mg/ml solución inyectable o concentrado para solución para perfusión, NEORECORMON 30000 UI/solución inyectable en jeringa precargada
ACROSS
ANEMIA EN PACIENTES ADULTOS CON TUMORES NO MIELOIDES EN TRATAMIENTO CON QUIMIOTERAPIA
 
 
2005-005938-12: Eine offene, nicht randomisierte, einarmige Pilotstudie zur Beurteilung der Wirksamkeit von Erythropoetin bei Friedreich Ataxie.

Ongoing
2
12
Europe
Neo-Recormon, EU1/97/031/031-032, Concentrate for solution for injection, Neo-Recormon
Dr. Sylvia Boesch
Die Friedreich Ataxie (FRDA) ist eine autosomal-rezessiv vererbte, progressive neurodegenerative Erkrankung, die mit einer Inzidenz von rund 1:50.000 auftritt. Es handelt sich dabei um die am häufigsten vorkommende Ataxie beim Menschen. Sie manifestiert sich klinisch initial als spinozerebelläre Ataxie, im weiteren Krankheitsverlauf tritt meist eine hypertrophe Kardiomyopathie hinzu, deren Komplikationen häufig für den frühen Tod der Patienten verantwortlich sind.
 
 
2004-005259-32: A phase 2 randomised trial to investigate the effects of recombinant human erythropoietin on infarct size in patients undergoing primary percutaneous coronary angiography for ST-segment elevation myocardial infarction.

Ongoing
2
124
Europe
NeoRecormon, NeoRecormon, NeoRecormon
Imperial College Heathcare NHS Trust
Acute ST elevation myocardial infarction
 
 
2006-003396-13: High-Dose Ribavirin in Combination With Standard Dose Peginterferon for Treatment of Chronic Hepatitis C Patients Who Are Nonresponders to Previous Standard Dosed Peginterferon/Ribavirin Combination Therapy

Ongoing
2
25
Europe
Copegus, Neorecormon, R20-9963/J10, Ro205-3859/V08, Ro205-3859/V52, R020-9963/F03, Copegus 200 mg, Neorecormon, Copegus 400 mg, Copegus 200 mg, Neorecormon, Copegus 400 mg
Karolinska University Hospital, Huddinge
Chronic hepatitis C
 
 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
recombinant human erythropoietin / Max Planck Institute, Pfizer
2008-000453-35: Open-label phase IIa pilot study exploring safety and potential efficacy of recombinant human erythropoietin in early mild Alzheimer Dementia and therapy-refractory Major Depression (“EPO-AD”)

Ongoing
2
20
Europe
Erypo, Erypo
Max-Planck-Institute of Experimental Medicine
Early, mild dementia of the Alzheimer’s Type and therapy-refractory Major Depression
 
 
Epomax (epoetin omega biosimilar) / Takeda
2004-000678-30: An Evaluation of the Efficacy of Epo-Omega in Treatment of Anaemia in ESRD Patients When Administered by Thrice Weekly Intravenous Injection: A Dose Dependency Evaluation.

Ongoing
2
35
Europe
NEORECORMON, EPOMAX 5000 IU, solution for injection, NeoRecormon Multidose 50,000IU Powder and solvent for solution for injection, NeoRecormon Multidose 50,000IU Powder and solvent for solution for injection
Baxter Healthcare S.A.
Anaemia in End Stage Renal Disease (ESRD) hemodialyzed Patients
 
 
Binocrit (epoetin alfa biosimilar) / Medice, Sandoz
2020-003388-24: Erythropoietin in Trauma

Not yet recruiting
3
2500
Europe
Binocrit 40,000 IU/1 mL solution for injection in a pre-filled syringe, Solution for injection in pre-filled syringe, Binocrit
University College Dublin, Monash University, HRB, NHMRC, Health Research Board
Traumatic injury, Severe injury, Diseases [C] - Injuries, poisonings, and occupational diseases [C21]
 
 
2019-000401-76: Transfusion savings in heart surgery Epargne transfusionnelle en chirurgie cardiaque

Not yet recruiting
3
128
Europe
Solution for injection, Solution for infusion, Solution for infusion in pre-filled syringe, FERINJECT, Venofer, Binocrit
University hospital of Montpellier, University hospital of Montpellier
Heart failure Défaillance cardiaque, Heart failure Défaillance cardiaque, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Surgical Procedures, Operative [E04]
 
 
EPO-TRAUMA, NCT04588311: ErythroPOietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill TRAUMA Patients

Recruiting
3
2500
Europe, RoW
Epoetin Alfa 40000 UNT/ML, Eprex, Binocrit, Sodium Chloride 0.9%, Placebo, Saline
Australian and New Zealand Intensive Care Research Centre, University College Dublin, Medical Research Institute of New Zealand, Medical Research Future Fund, Health Research Board, Ireland, Health Research Council, New Zealand, Irish Critical Care Clinical Trials Network, ANZICS Clinical Trials Group, Monash University
Trauma, Traumatic Injury, Traumatic Brain Injury, Wounds and Injuries, Penetrating Injury, Blunt Injury, Major Trauma, Multiple Trauma
12/25
12/25
ELEMENT-MDS, NCT05949684: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions

Recruiting
3
360
Europe, Canada, Japan, US, RoW
Luspatercept, BMS-986346, ACE-536, Reblozyl®, Epoetin Alfa, Epogen®, PROCRIT®, BINOCRIT
Bristol-Myers Squibb
Myelodysplastic Syndromes
06/27
03/30
darbepoetin alfa (NuPIAO) / 3SBio
NCT06854276: Study of SSS06 for Chemotherapy-Induced Anemia in Non-Myeloid Malignancies

Not yet recruiting
2
80
NA
SSS06, rhEPO, Yibiao
Shenyang Sunshine Pharmaceutical Co., LTD.
Chemotherapy-induced Anemia, Non-myeloid Malignancies
12/27
12/27
recombinant human erythropoietin biosimilar / Hua-Bao Pharma
ChiCTR1900024947: A randomized, open, parallel controlled, single-center clinical trial for recombinant human erythropoietin injection (CHO cells) in the treatment of anemia caused by chemotherapy in non-bone marrow malignant tumors at different times

Recruiting
4
80
 
Recombinant human erythropoietin injection (Jimaixin) 12000 IU/branch, one subcutaneous injection, three times a week (at least one day interval each time) for 8 weeks ;Recombinant human erythropoietin injection (Jimaixin) 12000 IU/branch, 3 branches per time, subcutaneous injection, once a week (3 branches per injection at different parts), for 8 weeks
Anyang Cancer Hospital; North China Pharmaceutical Jintan Biotechnology Co., Ltd., Enterprise self-financing
Tumor anemia
 
 
ChiCTR2000034705: Recombinant human erythropoietin injection (CHO cells) in the treatment of persistent peritoneal dialysis renal anemia: a randomized, positive parallel control, open multicenter clinical trial

Not yet recruiting
4
184
 
12000 IU/ piece, hypodermic injection ;10000 IU/ piece, hypodermic injection
The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine; NCPC Genetech Biotechnology Co.Ltd, Fully self-raised
renal anemia
 
 
EPIAO (recombinant human erythropoietin biosimilar) / 3SBio
EPIAO1: 3SBio Inc. (SSRX) Announces SFDA Approval of High-Dose EPIAO

Completed
3
206
China
EPIAO (recombinant human erythropoietin biosimilar)
3SBio
Anemia
 
 
Hematoboost, NCT05911438: Accelerated Recovery for Total Knee Replacement Surgery With Preoperative Intravenous Iron Combined With Human Erythropoietin for Rapid Hematopoietic Mobilization to Prevent Postoperative Anemia

Not yet recruiting
N/A
419
RoW
Ferric Derisomaltose Injection (Monoferric) and Human Erythropoietin Injection (EPIAO), Basic Treatment
West China Hospital
Total Knee Arthroplasty
12/24
06/25
Epogen (epoetin alfa) / Amgen
NCT05300477: Pharmacological Countermeasures for High Altitude

Active, not recruiting
4
18
US
Acetazolamide, Diamox, Erythropoietin, Procrit
United States Army Research Institute of Environmental Medicine, University of Puget Sound
Hypobaric Hypoxia
09/23
09/25
NCT05078138: Impact of Erythropoietin on Hematological Adaptations and Physical Performance

Completed
4
8
US
Epoetin Alfa
United States Army Research Institute of Environmental Medicine
Exercise-Induced Anemia, Physical Performance
04/23
04/23
NCT04134026: Evaluate the Efficacy and Safety of HIF-PHI for the Treatment of Anemia and Risks of Cardiovascular and Cerebrovascular Events in ESRD Newly Initiated Dialysis Patients

Not yet recruiting
4
400
RoW
HIF-PHI, Epoetin Alfa, Epogen
Second Xiangya Hospital of Central South University
Anemia in Incident Dialysis Patients
10/23
10/24
EpoAid, NCT06670963: Use of Epoetin Alfa and Iron Derisomaltose in Treatment of Anemia in Patients With Sepsis or Septic Shock: a Randomized Controlled Trial

Recruiting
4
200
Europe
Iron, EPO, 0.9 % NaCl
Piotr Czempik
Anemia, Sepsis, Septic Shock
12/26
04/27
NCI-2009-01173, NCT00843882: Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

Active, not recruiting
3
247
US
Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Epoetin Alfa, EPO, Epoetin alfa-epbx, Epogen, Eprex, Procrit, Retacrit, Laboratory Biomarker Analysis, Lenalidomide, CC 5013, CC-5013, CC5013, CDC 501, Revlimid
National Cancer Institute (NCI)
Anemia, Chronic Myelomonocytic Leukemia, De Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome
07/19
10/25
EPO-PRETAR, NCT03223961: A Trial Testing Early Vs Late Onset of EPO Alfa Treatment in Lower Risk MDS

Active, not recruiting
3
124
Europe
EPREX, Epoetin alfa
Groupe Francophone des Myelodysplasies
Myelodysplastic Syndromes
09/23
10/28
PAEAN, NCT03079167 / ACTRN12614000669695: - Erythropoietin for Hypoxic Ischaemic Encephalopathy in Newborns

Completed
3
313
RoW
Epoetin Alfa, Epogen, Procrit, Normal saline, 0.9% NaCl
University of Sydney, National Health and Medical Research Council, Australia
Hypoxic-Ischemic Encephalopathy
11/23
04/24
COMMANDS, NCT03682536 / 2017-003190-34: A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve

Hourglass Jan 2022 - Dec 2022 : Submission for anaemia
Checkmark Data from COMMANDS trial for patients with 1L lower-risk MDS
Oct 2022 - Oct 2022: Data from COMMANDS trial for patients with 1L lower-risk MDS
Hourglass May 2020 - Dec 2020 : Market entry for MDS
Hourglass Aug 2020 - Dec 2020 : Market entry in EU for myelodysplastic syndrome and beta-thalassemia
Active, not recruiting
3
363
Europe, Canada, Japan, US, RoW
Luspatercept, ACE-536, Epoetin alfa, EPREX®, ERYPO®, PROCRIT®
Celgene, Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Myelodysplastic Syndromes
03/23
09/27
VOICE, NCT06520826: Vafseo Outcomes In-Center Experience

Recruiting
3
2200
US
Vadadustat, Vafseo, Erythropoiesis Stimulating Agent, Epoetin alfa (EPOGEN), Methoxy polyethylene glycol-epoetin beta (Mircera), or Darbepoetin alfa (Aranesp)
USRC Kidney Research, Akebia Therapeutics
Anemia of Chronic Kidney Disease
06/26
06/26
ENCASE, NCT06352138: Comparative Study of Two Recombinant Human Erythropoietin Products in Chronic Kidney Disease Patients

Not yet recruiting
3
280
RoW
Experimental: Epoetin alfa Megalabs® Erythropoietin injectable in intravenous administration., Epoetin alfa Megalabs®, Human recombinant epoetin alfa, Active comparator: European Union licenced epoetin alfa, Epogen®, Human recombinant epoetin alfa
Megalabs, Azidus Laboratories
Anemia of Chronic Kidney Disease
03/27
03/27
ACTRN12613000504718: Dose finding study for Polysialylated Erythropoietin (PSA-EPO) in Chronic Kidney Disease (CKD) subjects

Recruiting
2
90
 
Xenetic Biosciences PLC, Xenetic Biosciences PLC
Anaemia in Chronic Kidney Disease
 
 
NCT05265325: A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis

Completed
2
175
US, RoW
AND017 capsules TIW, AND017 capsules QW, epoetin alfa, darbepoetin alfa, Mircera®, or their biosimilars
Kind Pharmaceuticals LLC
Renal Anemia
02/24
04/24
ACHiEvE-SCD, NCT05451940: Hydroxyurea and EPO in Sickle Cell Disease

Completed
1/2
17
US, RoW
Hydroxyurea, Droxia, Hydrea, and hydroxycarbamide., Epoetin Alfa, EPO, epoetin, erythropoietin, erythropoiesis-stimulating agent, ESA, haematopoietin, haemopoietin
Julia Xu, Carnegie Mellon University, American Society of Hematology
Anemia, Sickle Cell, Sickle Cell Disease
12/24
02/25
EVEREST, NCT06832189: EVR and EPO for Liver Transplant Tolerance

Not yet recruiting
1
20
US
Everolimus, Zortress, Epoetin alfa, EPO, Erythropoietin, Procrit
National Institute of Allergy and Infectious Diseases (NIAID)
Liver Transplant
06/30
06/30
NCT00090935: Epoetin Alfa in Treating Cancer-Related Anemia in Patients With Non-Myeloid Cancer Who Are Not Currently Receiving Chemotherapy or Radiation Therapy

Active, not recruiting
N/A
US
epoetin alfa
Jonsson Comprehensive Cancer Center, National Cancer Institute (NCI)
Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
 
 
NCT03061565: Long Term Effects of Erythropoietin in Patients With Moderate to Severe Traumatic Brain Injury

Completed
N/A
356
RoW
erythropoietin, EPOETIN ALFA, Placebos, Sodium chloride
Australian and New Zealand Intensive Care Research Centre, Monash University
Traumatic Brain Injury
07/22
12/22
CA056-1083, NCT06581055: A Retrospective Study to Describe Real-World Treatment Patterns and Clinical Outcomes Among Patients With Myelodysplastic Syndromes

Withdrawn
N/A
86
RoW
Luspatercept, Epoetin Alfa
Bristol-Myers Squibb
Myelodysplastic Syndromes (MDS)
03/25
03/25
Mircera (methoxy polyethylene glycol-epoetin beta) / Roche, CSL Behring
2009-011497-15: PILOT CLINICAL TRIAL WITH MIRCERA (methoxy polyethylene glycol-epoetin beta) IN DIALYSIS UNIT OF A.O. SAN GIOVANNI BATTISTA DI TORINO

Ongoing
4
21
Europe
MIRCERA*IV SC FL 200MCG 1ML, MIRCERA*IV SC FL 200MCG 1ML
AZIENDA SANITARIA OSPEDALIERA \"S. GIOVANNI BATTISTA DI TORINO\"
End stage renal patients in hemodialysis or peritoneal dialysis treatment
 
 
ROQ-IT, NCT05951192: A Prospective Interventional Study Assessing the Clinical and Operational Effectiveness of Transitioning From Mircera to Daprodustat for the Treatment of Anemia in End Stage Kidney Disease

Completed
4
161
US
Daprodustat, JESDUVROQ
USRC Kidney Research, GlaxoSmithKline
Anemia, Renal Insufficiency, Chronic, Renal Anemia
02/24
02/24
2010-021355-85: Etude nationale, multicentrique, prospective, évaluant la correction et le maintien du taux d’hémoglobine avec une administration sous-cutanée mensuelle de Mircera® chez des patients transplantés rénaux depuis plus de 6 mois présentant une anémie symptomatique traitée ou non par ASE

Ongoing
3
158
Europe
RO 503821/F03, MIRCERA, MIRCERA
CHU AMIENS
Anémie symptomatique chez le patient transplanté rénal
 
 
NCT04707768: Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects

Completed
3
456
US
Vadadustat, Mircera®
Akebia Therapeutics
Anemia Associated With Chronic Kidney Disease (CKD)
01/23
01/23
NCT04155125: A Study of Efepoetin Alfa in Treating Anaemia Associated With Chronic Kidney Diseases Patient

Completed
3
391
RoW
efepoetin alfa, Mircera
PT Kalbe Genexine Biologics, Novotech (Australia) Pty Limited
Anaemia Associated With Chronic Kidney Disease
03/22
06/23
NCT01892202: A Non-Interventional Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Patients With Chronic Kidney Disease Not on Dialysis

No Longer Available
N/A
RoW
Cohort
Hoffmann-La Roche
Anemia
02/11
02/11
ReliPoietin (recombinant human erythropoietin biosimilar) / Reliance Life Sci
Relipoietin1: A clinical trial to evaluate efficacy and safety of Relipoietin in patients with anemia due to Kidney disease

Completed
3
75
India
ReliPoietin (recombinant human erythropoietin biosimilar)
Reliance Life Sciences
Anemia
 
 
Nanokine (epoetin alfa biosimilar) / Nanogen Biopharma
EPO, NCT06919861: Pharmacokinetics, Pharmacodynamics, and Safety of Nanokine Produced by Nanogen Pharmaceutical Joint Stock Company

Not yet recruiting
1
44
NA
Erythropoietin alfa, Nanokine, Eprex
Nanogen Pharmaceutical Biotechnology Joint Stock Company
Natural Blood and Blood Product Toxicity
10/25
12/25
Repotin (recombinant human erythropoietin biosimilar) / Genius Biotherapeutics
epoetinZydCad: A clinical trial to study the effects of epoetin in patients with chronic renal failure

Completed
3
80
India
epoetin alfa biosimilar - Zydus Cadila
Zydus Cadila
Chronic Renal Failure
 
 
Epoyet (epoetin alfa biosimilar) / Procaps, Biogalenic, Delta Farma, Biosidus, Pentafarma
NCT04036253: Study of HEMAX PFS Versus EPREX/ ERYPO® in Predialysis Chronic Kidney Disease

Completed
3
43
RoW
Erythropoietin alfa
Bio Sidus SA
Anemia of Chronic Kidney Disease
06/21
08/21
Eprex (epoetin alfa) / J&J
2012-002076-14: Pre-operative treatment with Erythropoietin and iron supplement for prevention of perioperative blood transfusion in cardiac surgery Pre-operatieve behandeling met Erythropoietin en ijzer supplement ter voorkoming van peri-operatieve bloedtransfusie bij hartchirurgie.

Ongoing
4
100
Europe
EPREX, Ferinject, RVG33268, B03A C01, Suspension for injection in pre-filled syringe, Solution for injection/infusion, EPREX, Ferinject
Patients (male and female) scheduled for coronary artery bypass grafting surgery (CABG) or single Aortic Valve replacement (AVR) on conventional cardiopulmonary bypass., bloodloss in cardiac surgery, Diseases [C] - Cardiovascular Diseases [C14]
 
 
2011-000123-33: The use of erythropoietin (rhEPOa) in patients with stroke to see if it can aid and speed up the recovery and regrowth of new nerve cells.

Ongoing
4
90
Europe
EPREX, EPREX 40,000 IU/ml, solution for injection in pre-filled syringe., EPREX 40,000 IU/ml, solution for injection in pre-filled syringe.
King\'s College Hospital NHS Foundation Trust, King\'s College London, National Institute of Health Research
Stroke
 
 
2007-005831-27: Use of rHuEpo before autologous hematopoietic stem cell transplantation in patients affected by multiple myeloma, non Hodgkin disease and breast cancer to reduce transfusional requirement after myeloablative conditioning. A monocentric, phase III, open study.

Ongoing
3
90
Europe
EPREX, EPREX
AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA\' GRANDA (A.O. DI RILIEVO NAZIONALE)
autologous hematopoietic stem cells transplantation in patients affected by multiple myeloma, non Hodgkin disease and breast cancer
 
 
2009-016066-91: SAFETY AND EFFICACY OF ERYTHROPOIETIN IN AMYOTROPHIC LATERAL SCLEROSIS: A RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL

Ongoing
3
160
Europe
EPREX*1SIR 40000UI/ML 1ML, EPREX*1SIR 40000UI/ML 1ML
ISTITUTO NEUROLOGICO \"CARLO BESTA\"
ALS
 
 
2017-000812-41: A RANDOMIZED TRIAL TESTING EARLY VERSUS LATE ONSET OF EPO ALFA TREATMENT IN LOWER RISK MDS WITH NON RBC TRANSFUSION DEPENDENT ANEMIA AND WITHOUT DEL 5Q Etude randomisée évaluant l’introduction précoce versus tardive de l’Epoétine Alfa (EPREX®) chez les patients atteints de syndromes myélodysplasiques de bas risque

Not yet recruiting
3
124
Europe
Eprex, Injection, EPREX
GFM-Groupe Francophone des Myélodysplasies, Janssen
Adult subject (18 years of age older) with low or intermediate-1 IPSS risk MDS with transfusions independent anemia patients adultes (18 ans ou plus) avec SMD de risque IPPS faible ou intérmédiaire-1 présentant une anémie non-dépendante des transfusions, Adult subject (18 years of age older) with low or intermediate-1 IPSS risk MDS with transfusions independent anemia patients adultes (18 ans ou plus) avec SMD de risque IPPS faible ou intérmédiaire-1 présentant une anémie non-dépendante des transfusions, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2011-001329-26: Erythropoietin in Amyotrophic Lateral Sclerosis: a study to identify the best dose and the optimal route of administration and evaluate the safety Eritropoietina nella Sclerosi Laterale Amiotrofica: uno studio per identificare la dose e la via di somministrazione ottiminali e valutarne la sicurezza

Ongoing
2
40
Europe
Solution for injection, EPREX*1SIR 40000UI/ML 1ML
ISTITUTO NEUROLOGICO "CARLO BESTA", ARISLA
Amyotrophic Lateral Sclerosis Sclerosi Laterale Amiotrofica, Degenerative motoneuron disease Malattia degenerativa dei motoneuroni, Diseases [C] - Nervous System Diseases [C10]
 
 
2007-000994-40: ESTUDIO MULTICENTRICO PROSPECTIVO, DOBLE CIEGO, CONTROLADO CON PLACEBO, ALEATORIZADO, DE TRES GRUPOS PARALELOS PARA EVALUAR LA EFICACIA Y SEGURIDAD DEL TRATAMIENTO CON ERITROPOYETINA RECOMBINANTE HUMANA EN LA PREVENCIÓN DE LA NEFROTOXICIDAD ASOCIADA A LA UTILIZACIÓN DE CONTRASTES YODADOS EN PACIENTES CON ALTO RIESGO DE DISFUNCIÓN RENAL.

Ongoing
2
198
Europe
NEORECORMON 50.000 UI, EPREX 40.000 UI/1 ml, EPOPEN 40.000 UI/1 ml solución inyectable en viales, NEORECORMON 50.000 UI, EPREX 40.000 UI/1 ml, EPOPEN 40.000 UI/1 ml solución inyectable en viales
Hospital General \"Gregorio Marañón\"
Pacientes diagnosticados de enfermedad vascular periférica o coronaria, sometidos a procedimientos radiológicos diagnósticos o intervencionistas que incluyan la utilización de radiocontrastes, con alto riesgo de desarrollar nefropatía de contraste (Score de Mehran de >9 previo al procedimiento)
 
 
2015-002255-10: Can artificially made human erythropoietin improve recovery after major injuries?

Ongoing
2
10
Europe
Eprex (rhEPO), NA, Solution for injection in pre-filled syringe, Eprex
Abertawe Bro Morgannwg University Health Board, Abertawe Bro Morgannwg University Health Board
Post-trauma multiple organ failure: a manifestation of the systemic inflammatory/immune response to major injuries., This study will see if artificially made human erythropoietin helps people recover from serious injury quicker by boosting immunity through bone marrow or improving the way the body creates energy., Body processes [G] - Immune system processes [G12]
 
 
PRETEC-EPO, NCT03315897 / 2016-004023-24: Effects of Erythropoietin on Cognition and Neural Activity in Mood Disorders

Completed
2
103
Europe
Erythropoietin, Eprex, EPO, Saline, Placebo
Lars Vedel Kessing, Mental Health Services in the Capital Region, Denmark, Lundbeck Foundation
Bipolar Disorder, Cognitive Impairment, Unipolar Depression
10/22
10/22
EPO-T, NCT03339596 / 2016-002326-36: Effects of Erythropoietin for Cognitive Side-effects of ECT

Completed
2
60
Europe
Erythropoietin, Eprex, EPO, Saline, Placebo
Martin Balslev Jørgensen, The Augustinus Foundation, Denmark., Mental Health Services in the Capital Region, Denmark
ECT, Cognitive Impairment, Unipolar Depression, Bipolar Depression
01/23
02/23
2021-000596-37: A randomized phase I/ II multicenter study evaluating combination of luspatercept in LR-MDS without RS having failed or being ineligible to ESA Étude multicentrique de phase I/II randomisée évaluant luspatercept seul ou en association avec l’ASE (Agent Stimulant l’Erythropoïèse) dans les Syndromes Myélodysplasiques de faible risque non sidéroblastiques en échec ou non éligibles aux Agents Stimulants l’érythropoïèse

Ongoing
1/2
150
Europe
Eprex, Lyophilisate for solution for injection, Solution for injection, Reblozyl, EPREX
Groupe Francophone des Myélodysplasies, Celgene/BMS
Low risk myelodysplastic syndrom without RS having failed or being ineligible to Erythroid Stimulating Agent Syndromes Myélodysplasiques de faible risque non sidéroblastiques en échec ou non éligibles aux agents stimulants l’érythropoïèse, Low risk myélodysplastic syndrom without RS having failed or being ineligible to Erythroid Stimulating Agent Syndromes Myelodysplasiques de faible risque non sidéroblastiques en échec ou non éligibles aux agents stimulants l’érythropoïèse, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT05181735: Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA

Recruiting
1/2
150
Europe
Luspatercept Injection [Reblozyl], ACE-536, Eprex, Epoietin alfa
Groupe Francophone des Myelodysplasies, Celgene
MDS, Myelodysplastic Syndromes
12/28
06/29
2006-006898-24: Etude TETRAM 2 : Traitement par l’Epo des TRAumatisés Médullaires : recherche de la dose maximum tolérée

Ongoing
1
20
Europe
EPREX®, EPREX, EPREX
HOSPICES CIVILS DE LYON
traumatisme médullaire déficitaire (TMD)
 
 
RUBI, NCT04954989: Biosimilarity Study of Intravenous Recombinant Human Erythropoietin in Healthy Volunteers

Not yet recruiting
1
52
RoW
Experimental Erythropoietin subcutaneous injection single dose of 4,000 IU, Active comparator Erythropoietin subcutaneous injection single dose of 4,000 IU
Megalabs
Healthy
12/24
12/24
ErepoXen (polysialylated erythropoietin) / Xenetic Biosci, Serum Institute of India, Pharmsynthez
ErepoXen1: Dose finding study for Polysialylated Erythropoietin (PSA-EPO) in Chronic Kidney Disease (CKD) subjects

Recruiting
2
90
Australia, New Zealand
ErepoXen (polysialylated erythropoietin)
Xenetic Biosciences
Chronic Kidney Disease
 
 
Eporatio (epoetin theta biosimilar) / Merckle Biotec, Teva
ChiCTR1900024213: Clinical Trial of BioPoint ALT-1 Test

Not yet recruiting
N/A
 
Jiangsu Province Hospital; JiangSu Province Hospital, Projects to “improve capacity building for prevention and control of infectious diseases”
Liver diseases
 
 
HyPoietin (epoetin alfa biosimilar) / GC Biopharma, Genexine, Fosun Pharma
NCT06466785: A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis

Recruiting
3
429
RoW
Efepoetin Alfa, GX-E4, Darbepoetin Alfa, Aranesp®
Genexine, Inc., PT Kalbe Genexine Biologics
Anemia of Chronic Kidney Disease
12/26
09/27
GX-E4-HV-003, NCT06490939: Clinical Trial of Efepoetin Alfa in Healthy Subjects

Recruiting
1
40
RoW
Efepoetin Alfa, GX-E4
Genexine, Inc.
Healthy
02/25
10/25
Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin
2005-003057-28: An Investigation Into the Prevalence, Cause and treatment of Unexplained Anamia in Diabetes

Ongoing
4
1000
Europe
Neorecormon, Aranesp, N/A, Neorecormon, Aranesp, Neorecormon, Aranesp
University Hospital Aintree NHS Trust
Anaemia in Diabetes
 
 
2010-020401-32: IDENTIFICATION OF OXIDATIVE-STRESS AND MICROINFLAMMATION GENES MODULATED BY ERYTHROPOIETIN ADMINISTRATION IN PATIENTS WITH RENAL TRANSPLANT AND CHRONIC RENAL FAILURE. PERSPECTIVES FOR ERYTHROPOITIN PHARMACOGENOMICS.

Ongoing
4
20
Europe
ARANESP, ARANESP
AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE
PATIENTS WITH RENAL TRANSPLANT AND CHRONIC RENAL FAILURE
 
 
NCT05864261: Pharmacokinetics Comparison Study of JT1801 and NESP® After Single Dose Administration in Chinese Health Male Volunteers

Completed
4
74
RoW
JT1801 60ug, NESP 60ug
Yi Fang
Renal Anemia
08/23
08/23
ChiCTR2200057105: The effect of darbepoetin alfa on patients with chronic renal disease and renal anemia (A real-world study)

Not yet recruiting
4
 
Shenzhen Second People's Hospital, the First Affiliated Hospital of Shenzhen University; Shenzhen Second People's Hospital, the First Affiliated Hospital of Shenzhen University, None
chronic kidney disease and renal anemia
 
 
ChiCTR2500096455: Protocol for Comparing Hemoglobin Control between Darbepoetin Alfa and Short-acting rHuEPO in Maintenance Hemodialysis Patients

Not yet recruiting
4
410
 
No; No
Shenzhen Second People's hospital; Shenzhen Second People's hospital, National Natural Science Foundation of China (81900639); Basic Research Program of Shenzhen Science and Technology R&D Fund (JCYJ20190806162807125); Shenzhen Key Medical Discipline Construction Fund (SZXK009); Sanming Project of Medicine in Shenzhen(SZSM201512004)
Renal anemia
 
 
2007-001904-18: An open label randomised controlled study to compare the efficacy, safety and tolerability of once every four weeks administration of subcutaneous C.E.R.A. versus darboepoetin alfa for the maintenance of haemoglobin levels in predialysis patients with chronic renal anaemia.Estudio abierto, randomizado, controlado para comparar la eficacia, seguridad y tolerancia de la administración una vez cada cuatro semanas de C.E.R.A. por vía subcutánea frente a darbepoetina alfa para el mantenimiento de las concentraciones de hemoglobina en pacientes con anemia renal crónica que no están en diálisis.

Ongoing
3
297
Europe
C.E.R.A., C.E.R.A, RO0503821, Aranesp®, Aranesp®
ROCHE FARMA S.A.
Anemia en insuficiencia renal crónica
 
 
2007-001905-10: \"Estudio abierto, randomizado, controlado para comparar la eficacia, seguridad y tolerancia de la administración una vez cada cuatro semanas de C.E.R.A por vía subcutánea frente a darbepoetina alfa para el mantenimiento de las concentraciones de hemoglobina en pacientes receptores de trasplante renal con anemia renal crónica \"\"An open label randomised controlled study to compare the efficacy, safety and tolerability of once each four weeks administration of subcutaneous C.E.R.A. versus darbepoetin alfa for the maintenance of haemoglobin levels in renal transplant recipients with chronic renal anaemia\"

Ongoing
3
297
Europe
C.E.R.A, RO0503821, Aranesp, Aranesp
Roche Farma S.A
Nefropatía crónica en pacientes transplantados
 
 
2007-003509-28: Intérêt de l’administration intra-coronaire d’une dose unique d’EPO lors de la reperfusion chez des patients hospitalisés pour un primo infarctus avec sus-décalage persistant du segment ST

Ongoing
3
54
Europe
ARANESP, ARANESP, ARANESP
CHRU Montpellier - Direction de la Recherche, Partenariats et Réseaux, Relations avec l\'Université
Patients hospitalisés pour un primo infarctus avec sus-décalage persistant du segment ST
 
 
2017-000583-15: Randomized controlled trial on the use of darbepoetin alfa to reduce red cell transfusions in newborns with hemolytic disease due to red cell alloimmunization treated with intrauterine transfusions

Ongoing
3
40
Europe
Solution for injection, Aranesp
Leiden University Medical Center, Sanquin Blood Supply
Hemolytic disease of the newborn due to red blood cell alloimmunization, Anemia in the newborn due to red cell antibodies received from the mother (for example rhesus D hemolytic disease), Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
 
 
NCT05585645: A Study to Compare Efficacy and Safety of Nanogen's Darbepoetin Alfa With Aranesp® (Amgen) in the Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis (CKD)

Completed
3
214
RoW
Stimus (NNG-DEPO)
Nanogen Pharmaceutical Biotechnology Joint Stock Company, Vietstar Biomedical Research, MEDPHASE CLINICAL RESEARCH CONSULTANT COMPANY LIMITED, CLINICAL RESEARCH VIET NAM SKILL TRAINING AND CONSULTING COMPANY LIMITED, MedProve Inc
Anemia, Chronic Kidney Disease Requiring Chronic Dialysis
11/22
11/22
NCT05768997: High Dose IV Iron Plus ESA in Chemotherapy-induced Anemia

Recruiting
3
312
RoW
Ferric Derisomaltose Injection, Darbepoetin Alfa Injection
Hallym University Medical Center
Anemia
12/25
12/25
ACTRN12605000731695: Phase II study of the addition of darbepoetin alfa (Aranesp) and pegfilgrastim (Neulasta) support for optimal dose-dense chemotherapy for early breast cancer

Not yet recruiting
2
30
 
Mater Adult hospital, Mater Adult Hospital
Breast Cancer
 
 
ACTRN12606000030572: An open label phase 2 study of doxorubicin and cyclophosphamide followed by paclitaxel (AC-T) delivered every 14 days with pegfilgrastim and darbepoetin alfa support for the adjuvant treatment of women with breast cancer

Recruiting
2
80
 
Amgen Australia, Amgen Australia
Early stage breast cancer
 
 
NCT00039247: Darbepoetin Alfa in Treating Anemia in Patients With Cancer Who Are Receiving Chemotherapy

Active, not recruiting
2
NA
darbepoetin alfa
Jonsson Comprehensive Cancer Center, National Cancer Institute (NCI)
Anemia, Unspecified Adult Solid Tumor, Protocol Specific
 
 
2007-003153-90: Traitement par érythropoïétine de l\'anémie associée à la bronchopneumopathie chronique obstructive : conséquences fonctionnelles à l\'effort

Ongoing
2
20
Europe
ARANESP, ARANESP, ARANESP
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
Anémie associée à la BPCO
 
 
2007-007137-38: En åbent randomiseret fase II undersøgelse af effekten af darbepoietin alfa (Aranesp®) til behandling af anæmi hos patienter med hormonrefraktær prostatacancer, der behandles med Taxotere

Ongoing
2
100
Europe
Aranesp, Aranesp, Aranesp
Vejle Hospital
Patients with advanced prostate cancer and anaemia
 
 
2007-007653-31: Estudio aleatorizado, doble ciego, controlado con placebo, de 6 meses de duración para evaluar la eficacia de eritropoyetina recombinante humana en pacientes con ataxia de Friedreich.Randomized, double-blind, placebo-controlled 6 months study to evaluate the efficacy of rhuEPO in patients with Friedreich?s ataxia.

Ongoing
2
30
Europe
ARANESP 10 microgramos solución inyectable en jeringa precargada, ARANESP 20 microgramos solución inyectable en jeringa precargada, ARANESP 30 microgramos solución inyectable en jeringa precargada, ARANESP 50 microgramos solución inyectable en jeringa precargada, ARANESP 60 microgramos solución inyectable en jeringa precargada, ARANESP 80 microgramos solución inyectable en jeringa precargada, ARANESP 100 microgramos solución inyectable en jeringa precargada, ARANESP 130 microgramos solución inyectable en jeringa precargada, ARANESP 150 microgramos solución inyectable en jeringa precargada, ARANESP 10 microgramos solución inyectable en jeringa precargada, ARANESP 20 microgramos solución inyectable en jeringa precargada, ARANESP 30 microgramos solución inyectable en jeringa precargada, ARANESP 50 microgramos solución inyectable en jeringa precargada, ARANESP 60 microgramos solución inyectable en jeringa precargada, ARANESP 80 microgramos solución inyectable en jeringa precargada, ARANESP 100 microgramos solución inyectable en jeringa precargada, ARANESP 130 microgramos solución inyectable en jeringa precargada, ARANESP 150 microgramos solución inyectable en jeringa precargada
Fundación Investigación Biomédica Hospital La Paz
Ataxia de FriedreichFriedreich´s ataxiaCIE : 334,0
 
 
2017-002268-42: Anemia Studies in CKD: Erythropoiesis via a Novel PHI Daprodustat –Forearm Blood Flow (ASCEND-FBF)

Not yet recruiting
2
62
Europe
daprodustat 1mg, daprodustat 2mg, daprodustat 4mg, Darbepoetin alfa, Tablet, Solution for injection in pre-filled syringe, Aranesp
GlaxoSmithKline Research & Development Ltd, GlaxoSmithKline R&D
anemia associated with chronic kidney disease, anemia associated with chronic kidney disease, Body processes [G] - Physiological processes [G07]
 
 
EDEN, NCT04432662: Darbepoetin in Neonatal Encephalopathy Trial

Recruiting
2
150
Europe
Darbepoetin Alfa
Imperial College London
Neonatal Encephalopathy
09/24
09/24
DINOSAUR, NCT03171818: Darbepoetin for Ischemic Neonatal Stroke to Augment Regeneration

Recruiting
2
80
Europe
Darbepoetin Alfa, Aranesp, Saline, Sodium Chloride
UMC Utrecht, Alberta Children's Hospital, The Hospital for Sick Children
PAIS, Neonatal Stroke, Perinatal Stroke
12/24
06/25
FOXTROT, NCT05810311: The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy

Not yet recruiting
2
30
Europe
Roxadustat, Evrenzo, Darbepoietin Alfa, Aranesp
Region Stockholm
Diabetes Complications, Diabetes; Nephropathy (Manifestation)
01/27
12/27
DIVI, NCT05340465: Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants

Recruiting
2
120
US
Darbepoetin Alfa, Aranesp, Darbe, Low Molecular Weight Iron Dextran, INFeD, LMW-ID, Ferumoxytol injection, Feraheme, FMX, Oral iron supplements, Ferr-in-sol
University of Washington, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Prematurity, Iron-deficiency, Iron Deficiency Anemia, Iron Malabsorption
12/25
12/27
NCT04798339: Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA

Active, not recruiting
1/2
13
US
Canakinumab Injection, Ilaris, Darbepoetin Alfa, Aranesp
H. Lee Moffitt Cancer Center and Research Institute, Novartis Pharmaceuticals
Myelodysplastic Syndromes
05/25
10/25
CKD, NCT05636891: Pharmacokinetic/Pharmacodynamic Parameters of NNG-DEPO (Stimus) With Aranesp® (Amgen) in Treatment of Anemia in Patients on Dialysis

Completed
1
43
RoW
Stimus
Nanogen Pharmaceutical Biotechnology Joint Stock Company, Vietstar Biomedical Research, Clinical Research Consultants, Inc., Clinical Research Viet Nam Skill Training And Consultant Company Limited
Chronic Kidney Disease
11/22
11/22
SMART, NCT05936021: Clinical Validation Study for Optimization of Anemia MAnagement in Hemodialysis Patients With End Stage Kidney Disease Using the Dialysis Anemia TReatmenT Model

Active, not recruiting
N/A
80
US
Algorithm model-based Aranesp doses, Standard of care
Intermountain Health Care, Inc.
Dialysis
11/24
01/25
EPOASA, NCT04330729: The Effect of Salicylate on Platelet Function in CKD (Chronic Kidney Disease) Patients Treated With Aranesp

Recruiting
N/A
60
Europe
Acetylsalicylic acid
Zealand University Hospital
Erythropoietin Adverse Reaction
12/26
12/26
fezagepras (PBI-4050) / Liminal BioSci
2016-004823-21: A Rollover Study of PBI-4050 (study drug) in Patients with Alström Syndrome

Not yet recruiting
2
30
Europe
PBI-4050, Capsule, soft
Prometic Biosciences Inc., Prometic Biosciences Inc.
Alström Syndrome, A rare genetic disorder caused by mutations in the gene ALMS1, Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
 
 
EPEG (pegylated recombinant erythropoietin) / Cadila, Prolong Pharma
ACTRN12613000374763: A Phase 1 Single Blind, Randomized, Single-Dose, Safety, Tolerability, Pharmacodynamic, and Pharmacokinetic Study of ZY7318 (pegylated recombinant human erythropoietin) in Healthy Volunteers

Recruiting
1
32
 
Prolong Pharmaceuticals, LLC, Prolong Pharmaceuticals, LLC
Healthy volunteers study and investigational product would be targeted for secondary anemia due to renal cause.
 
 
Erysaa (epoetin alfa biosimilar) / PanGen Biotech, CCM Pharma
PDA10a: CCM Duopharma Biotech Berhad To Commence Historic Phase III Clinical Trials For Treatment Of Kidney Failure

Ongoing
3
300
Malaysia
PDA10 (epoetin alfa biosimilar)
PanGen Biotech
Kidney Failure
 
 
APO-EPO (epoetin alfa biosimilar) / Apotex
2011-005057-31: Study of safety and efficacy of APO-EPO versus US licensed Procrit® in patients with anemia of chronic kidney disease stage 5D

 
3
155
Europe
n/a, APO-EPO, n/a, Procrit®, Procrit®
APOTEX Inc., APOTEX Inc.
Anemia and chronic kidney disease stage 5D (patients on stable hemodialysis)
 
 
pegol sihematide (EPO-018B) / Jiangsu Hansoh Pharma
NCT06946394: Two Different Regiments of Pegmolesatide for Anemia in Patients With Chronic Kidney Disease Not Receiving Dialysis

Not yet recruiting
4
160
NA
Pegmolesatide, EPO-018B
The First Affiliated Hospital of Dalian Medical University, Jiangsu Hansoh Pharmaceutical Co., Ltd.
Renal Anemia in Non-dialysis Chronic Kidney Disease
06/26
11/26
NCT03902691: Study of the Efficacy and Safety of Pegol-Sihematide for Anemia in Patients With Chronic Kidney Disease on Dialysis

Completed
3
372
RoW
Pegol-Sihematide, ESPO
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Chronic Kidney Diseases
02/21
05/22
NCT03903809: Study of the Efficacy and Safety of Pegol-Sihematide for Anemia in Patients With NDD-CKD

Active, not recruiting
3
175
RoW
Pegol-Sihematide, HS-20039, ESPO, Recombinant Human Erythropoietin Injection
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Non-Dialysis-Dependent Chronic Kidney Disease
10/21
12/22
Epoch (epoetin beta biosimilar) / Roche
2006-004775-35: The Effect of Treating Patients with Anaemia in Diabetic Nephropathy to different target haemoglobin levels with Epoetin Beta

Ongoing
4
120
Europe
NeoRecormon, NeoRecormon
Barts and the London NHS Trust
Anaemia in Diabetic Nephropathy
 
 
2006-003502-26: A randomised control trial of the use of Epoetin Beta in the treatment of Post Transplant Anaemia

Ongoing
4
120
Europe
NeoRecormon, NeoRecormon
Barts and the London NHS Trust
Post Transplant Anaemia
 
 
2006-005373-22: Erythropoietin and Delayed Graft Function in Renal Allografts from Extended Criteria Donors.

Ongoing
4
40
Europe
NeoRecormon, NeoRecormon
Central Manchester and Manchester Children\'s University Hospitals NHS Trust
Transplantation of renal allografts from extended criteria donors
 
 
2007-001751-19: Estudio aleatorizado, unicéntrico, fase IV, para evaluar la corrección de la anemia asociada a la estenosis aórtica severa.

Ongoing
4
90
Europe
Neorecormon 10.000 U/semanales, Tardyferon, Neorecormon 10.000 U/semanales, Tardyferon
Dr. Miquel Gómez. Servicio de Cardiología. Hospital del Mar
Anemia asociada a la estenosis aórtica severa.
 
 
2007-001325-96: Estudio de dos pautas de hierro intravenoso para la optimización del tratamiento con epoetina recombinante humana en pacientes con anemia inducida por la radio quimioterapia

Ongoing
4
78
Europe
Venofer, Neorecormon, Venofer, Neorecormon, Venofer, Neorecormon
Pilar Samper Ots
Anemia en pacientes adultos con tumores sólidos tratados con radio-quimioterapia.
 
 
2008-003733-24: A randomised study to assess the effects of Epoetin Beta on renal function in patients with critical illness(with or without multi-organ failure)

Ongoing
4
30
Europe
Neo-recormon, EU/1/97/031/030, Neorecormon solution for injection (pre filled syringe), Neorecormon solution for injection (pre filled syringe)
Abertawe Bro Morgannwg University NHS Trust, Abertawe Bro Morgannwyg University Health Board
Sepsis/Acute renal failure
 
 
2006-003727-37: A randomized, open label, multicentre trial to define the most effective haemoglobin concentration to start erythropoietin beta (neoRecormon) therapy in anaemic subjects with lymphoproliferative malignancy receivin chemotherapy\"REPOS\"study

Ongoing
3
150
Europe
NeoRecormon,
Haga Teaching Hospital
Anemia in cancer patients
 
 
2009-011187-11: “Estudio fase III multicéntrico, aleatorizado y abierto de dos pautas de hierro intravenoso en combinación con epoetina beta para el tratamiento de la anemia inducida por quimioterapia en pacientes con cáncer no mieloide avanzado”.

Ongoing
3
200
Europe
VENOFER 20 mg/ml solución inyectable o concentrado para solución para perfusión, NEORECORMON 30000 UI/solución inyectable en jeringa precargada, VENOFER 20 mg/ml solución inyectable o concentrado para solución para perfusión, NEORECORMON 30000 UI/solución inyectable en jeringa precargada
ACROSS
ANEMIA EN PACIENTES ADULTOS CON TUMORES NO MIELOIDES EN TRATAMIENTO CON QUIMIOTERAPIA
 
 
2005-005938-12: Eine offene, nicht randomisierte, einarmige Pilotstudie zur Beurteilung der Wirksamkeit von Erythropoetin bei Friedreich Ataxie.

Ongoing
2
12
Europe
Neo-Recormon, EU1/97/031/031-032, Concentrate for solution for injection, Neo-Recormon
Dr. Sylvia Boesch
Die Friedreich Ataxie (FRDA) ist eine autosomal-rezessiv vererbte, progressive neurodegenerative Erkrankung, die mit einer Inzidenz von rund 1:50.000 auftritt. Es handelt sich dabei um die am häufigsten vorkommende Ataxie beim Menschen. Sie manifestiert sich klinisch initial als spinozerebelläre Ataxie, im weiteren Krankheitsverlauf tritt meist eine hypertrophe Kardiomyopathie hinzu, deren Komplikationen häufig für den frühen Tod der Patienten verantwortlich sind.
 
 
2004-005259-32: A phase 2 randomised trial to investigate the effects of recombinant human erythropoietin on infarct size in patients undergoing primary percutaneous coronary angiography for ST-segment elevation myocardial infarction.

Ongoing
2
124
Europe
NeoRecormon, NeoRecormon, NeoRecormon
Imperial College Heathcare NHS Trust
Acute ST elevation myocardial infarction
 
 
2006-003396-13: High-Dose Ribavirin in Combination With Standard Dose Peginterferon for Treatment of Chronic Hepatitis C Patients Who Are Nonresponders to Previous Standard Dosed Peginterferon/Ribavirin Combination Therapy

Ongoing
2
25
Europe
Copegus, Neorecormon, R20-9963/J10, Ro205-3859/V08, Ro205-3859/V52, R020-9963/F03, Copegus 200 mg, Neorecormon, Copegus 400 mg, Copegus 200 mg, Neorecormon, Copegus 400 mg
Karolinska University Hospital, Huddinge
Chronic hepatitis C
 
 
 

Download Options